知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.031 秒)

    Method for Determining Resistance of Hiv to Nucleoside Reverse Transcriptase Inhibitor Treatment
    1.
    发明申请
    Method for Determining Resistance of Hiv to Nucleoside Reverse Transcriptase Inhibitor Treatment 审中-公开
    用于确定核苷逆转录酶抑制剂治疗抗性的方法

    公开(公告)号：US20080293038A1

    公开(公告)日：2008-11-27

    申请号：US11915307

    申请日：2006-05-25

    申请人： Neil T. Parkin ,  Colombe Chappey ,  Jeannette Whitcomb

    发明人： Neil T. Parkin ,  Colombe Chappey ,  Jeannette Whitcomb

    IPC分类号： C12Q1/70

    CPC分类号： C12Q1/6883 ,  C12Q2600/156

    摘要： The present invention provides methods and devices for predicting whether an HIV-1 is resistant to an antiviral drug based on the HIV-1's genotype. In one aspect, the invention provides methods comprising determining whether a mutation or combination of mutations associated with NRTI resistance are present, as disclosed herein, thereby assessing the effectiveness of FTC therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV-1 resistance are provided.

    摘要翻译： 本发明提供了用于预测HIV-1是否对基于HIV-1的基因型的抗病毒药具有抗性的方法和装置。 一方面，本发明提供了如本文所公开的确定是否存在与NRTI抗性相关的突变或突变的组合的方法，从而评估FTC治疗在HIV感染的受试者中的有效性。 提供了确定HIV-1抗性的计算机实施方法。

    Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
    2.
    发明授权
    Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors 有权
    用于确定致病病毒对蛋白酶抑制剂的敏感性的组合物和方法

    公开(公告)号：US07993824B2

    公开(公告)日：2011-08-09

    申请号：US10612603

    申请日：2003-07-01

    申请人： Colombe Chappey ,  Christos J. Petropoulos ,  Neil T. Parkin

    发明人： Colombe Chappey ,  Christos J. Petropoulos ,  Neil T. Parkin

    IPC分类号： C12Q1/70 ,  C12Q1/68 ,  G01N33/00

    CPC分类号： C12Q1/703

    摘要： The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.

    摘要翻译： 本发明提供了一种基于通过表型临床切片指导的配对表型和基因型数据的综合分析来开发用于确定抗病毒药物有效性的算法的方法。 在一个方面，算法允许给患者提供有效的治疗。 它有助于预测受感染的个体是否会对抗病毒化合物进行治疗反应，从而允许设计有效的治疗方案，而不会对患者造成不必要的副作用。 此外，通过避免无效药物的管理，节省了大量的时间和金钱。

    METHOD FOR DETERMINING RESISTANCE OF HIV TO PROTEASE INHIBITOR TREATMENT
    5.
    发明申请
    METHOD FOR DETERMINING RESISTANCE OF HIV TO PROTEASE INHIBITOR TREATMENT 审中-公开
    用于确定HIV对蛋白酶抑制剂治疗的抗性的方法

    公开(公告)号：US20100070184A1

    公开(公告)日：2010-03-18

    申请号：US12160693

    申请日：2007-01-19

    申请人： Neil T. Parkin ,  Colombe Chappey

    发明人： Neil T. Parkin ,  Colombe Chappey

    IPC分类号： C12Q1/70 ,  G06F19/00

    CPC分类号： C12Q1/703 ,  G16B20/00 ,  G16B40/00

    摘要： The present invention provides methods and devices for predicting whether an HIV-I is likely to have a reduced susceptibility to an antiviral drug based on the HIV-I's genotype. In one aspect, the invention provides methods comprising determining whether a mutation or combination of mutations associated with altered susceptibility to protease inhibitors are present, as disclosed herein, thereby assessing the effectiveness of tipranavir therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV-I's altered susceptibility are provided.

    摘要翻译： 本发明提供了用于预测HIV-1基于HIV-1基因型是否可能对抗病毒药物的易感性降低的方法和装置。 一方面，本发明提供了如本文所公开的确定突变或与蛋白酶抑制剂的易感性相关的突变的组合是否存在的方法，从而评估了在HIV感染的受试者中替诺韦韦治疗的有效性。 提供了确定HIV-1改变易感性的计算机实施方法。

    Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
    6.
    发明授权
    Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors 有权
    用于确定致病病毒对蛋白酶抑制剂的敏感性的组合物和方法

    公开(公告)号：US07384734B2

    公开(公告)日：2008-06-10

    申请号：US10367223

    申请日：2003-02-13

    申请人： Neil T. Parkin ,  Colombe Chappey ,  Christos J. Petropoulos

    发明人： Neil T. Parkin ,  Colombe Chappey ,  Christos J. Petropoulos

    IPC分类号： C12Q1/70

    CPC分类号： C12Q1/703 ,  C12Q2600/156

    摘要： The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.

    摘要翻译： 本发明提供了一种基于通过表型临床切片指导的成对表型和基因型数据的综合分析来开发用于确定抗病毒药物有效性的算法的方法。 在一个方面，算法允许给患者提供有效的治疗。 它有助于预测受感染的个体是否会对抗病毒化合物进行治疗反应，从而允许设计有效的治疗方案，而不会对患者造成不必要的副作用。 此外，通过避免无效药物的管理，节省了大量的时间和金钱。

    Methods for determining the presence of antibodies blocking viral infection
    7.
    发明授权
    Methods for determining the presence of antibodies blocking viral infection 有权
    测定阻断病毒感染的抗体存在的方法

    公开(公告)号：US09175355B2

    公开(公告)日：2015-11-03

    申请号：US12635539

    申请日：2009-12-10

    申请人： Douglas Richman ,  Mary T. Wrin ,  Susan Little ,  Christos J. Petropoulos ,  Neil T. Parkin ,  Jeannette Whitcomb ,  Wei Huang

    发明人： Douglas Richman ,  Mary T. Wrin ,  Susan Little ,  Christos J. Petropoulos ,  Neil T. Parkin ,  Jeannette Whitcomb ,  Wei Huang

    IPC分类号： C12Q1/70 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/569 ,  C07K14/16 ,  C07K16/08 ,  C07K14/005 ,  C07K16/10

    CPC分类号： G01N33/56988 ,  C07K14/005 ,  C07K14/16 ,  C07K14/162 ,  C07K16/08 ,  C07K16/10 ,  C12Q1/6897 ,  C12Q1/703 ,  G01N33/5044 ,  G01N33/5091 ,  G01N33/56983 ,  G01N2333/16

    摘要： The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

    摘要翻译： 本发明提供了鉴定化合物是否抑制病毒进入细胞的方法，该方法包括：（a）从病毒感染的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生 使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入 进入第二个细胞。

    Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs
    8.
    发明授权
    Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs 有权
    确定HIV-1与抗HIV药物易感性变化的方法和组合物

    公开(公告)号：US08637252B2

    公开(公告)日：2014-01-28

    申请号：US13296370

    申请日：2011-11-15

    申请人： Soumi Gupta ,  Signe Fransen ,  Ellen Paxinos ,  Neil T. Parkin

    发明人： Soumi Gupta ,  Signe Fransen ,  Ellen Paxinos ,  Neil T. Parkin

    IPC分类号： C12Q1/68 ,  C12Q1/70 ,  A61K49/00

    CPC分类号： C12Q1/703 ,  C12Q2600/156

    摘要： This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus (“HIV”) to the non-nucleoside reverse transcriptase inhibitors (“NNRTIs”) efavirenz (“EFV”), nevirapine (“NVP”), and delavirdine (“DLV”), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.

    摘要翻译： 本发明部分地涉及用于确定人类免疫缺陷病毒（“HIV”）对非核苷逆转录酶抑制剂（“NNRTI”）依法韦仑（“EFV”），奈韦拉平（“NVP”）的改变的易感性的方法和组合物， ）和地拉呋啶（“DLV”），核苷逆转录酶抑制剂AZT和整合酶链转移抑制剂二酮酸1，二酮酸2和L-870,810，通过检测编码基因中的突变或突变的组合的存在 与抗HIV药物易感性改变相关的HIV逆转录酶。

    Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs
    9.
    发明授权
    Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs 有权
    使用患者衍生的包膜蛋白构建体评估病毒进入抑制剂的方法

    公开(公告)号：US07169551B2

    公开(公告)日：2007-01-30

    申请号：US11323189

    申请日：2005-12-29

    申请人： Christos J. Petropoulos ,  Neil T. Parkin ,  Jeanette Whitcomb ,  Wei Huang

    发明人： Christos J. Petropoulos ,  Neil T. Parkin ,  Jeanette Whitcomb ,  Wei Huang

    IPC分类号： C12Q1/70

    CPC分类号： C12Q1/70 ,  C12Q1/6897 ,  C12Q1/703 ,  G01N33/5091 ,  G01N33/56983

    摘要： The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

    摘要翻译： 本发明提供了一种用于鉴定化合物是否抑制病毒进入细胞的方法，其包括：（a）从感染病毒的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生 使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入 进入第二个细胞。